Clinical trial · Interventional
SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients
NCT05313074CI-TRIAL-00057859completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| COVID-19 | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CoronaVac vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Healthy volunteers
- description
- Healthcare workers at National Cancer Institute
- interventionNames
- Biological: CoronaVac vaccine
- type
- ACTIVE_COMPARATOR
- label
- Cancer patients
- description
- Cancer patients were divided into 3 groups based on treatment status including 1. active cancer on treatment 2. Planned to start treatment 3. Post-treatment (\<6 months)
- interventionNames
- Biological: CoronaVac vaccine
Primary outcomes (1)
- measure
- Immune response of Coronavac vaccine in Thai cancer patients
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or Female age at least 18 years * Patients with a diagnosis of solid tumors * Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure * Willing and able to comply with the study procedures. * Willing to receive a Coronavac vaccine (Sinovac). Exclusion Criteria: * Patients who cannot provide consent
References
Publications (0)
Data not yet available
No reference posted for this study.